amdoxovir + zidovudine

Amdoxovir + zidovudine is a combination of two small molecule nucleoside reverse transcriptase inhibitors (NRTIs) developed for the treatment of human immunodeficiency virus (HIV) infection. Amdoxovir acts synergistically with zidovudine, with the combination showing enhanced antiviral potency and reduced selection of common resistance mutations, including thymidine analogue mutations (TAMs) and the K65R mutation[1][2][3]. Mechanistically, both compounds inhibit HIV-1 reverse transcriptase, but through different activation/phosphorylation pathways (amdoxovir via 5'-nucleotidase and zidovudine via thymidine kinase)[2], and do not negatively impact each other's active nucleoside triphosphate levels in vitro[2][3]. Clinical data suggest the combination provides greater and more consistent reductions in viral load compared to the agents alone, especially with lower-dose zidovudine, and may delay the emergence of NRTI resistance[1][2][3]. All observed adverse events in clinical studies were mild to moderate[1].

Other names

amdoxovir + zidovudine